Related Experiment Videos
Allogeneic peripheral blood stem cell transplantation for leukemia
1Department of Hematology, First Affiliated Hospital, Medical College of Jinan University, Guangzhou 510632, China. ezengh1@zlcn.com
Chinese Medical Journal
|January 10, 2002
Summary
Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) offers rapid blood count recovery. While acute graft-versus-host disease (GVHD) is not increased, chronic GVHD remains a significant risk.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) is a crucial treatment for hematologic malignancies.
- Understanding engraftment kinetics and graft-versus-host disease (GVHD) is vital for optimizing patient outcomes.
Purpose of the Study:
- To evaluate engraftment kinetics, GVHD incidence and severity, and clinical outcomes in leukemia patients undergoing allo-PBSCT.
- To assess the safety and efficacy of allo-PBSCT using a busulfan-cyclophosphamide conditioning regimen.
Main Methods:
- Forty leukemia patients received allo-PBSCT, with peripheral blood stem cells mobilized by G-CSF.
- Conditioning regimen included busulfan-cyclophosphamide (BU-CY).
- GVHD prophylaxis utilized cyclosporine A with either methotrexate or methylprednisolone.
Main Results:
- Neutrophil and platelet engraftment occurred at median 13 and 12 days, respectively.
- Acute GVHD (grade II-IV) occurred in 25% of patients; chronic GVHD in 70%.
- Three-year leukemia-free survival was 72.5%, with 17.5% transplant-related mortality and 10% relapse rate.
Conclusions:
- Allo-PBSCT facilitates rapid hematopoietic reconstitution.
- The procedure does not increase the incidence of acute GVHD.
- A high risk of chronic GVHD is associated with allo-PBSCT.